Reviva Pharmaceuticals stock faces Nasdaq delisting after failing $1 minimum bid requirement
PUBT · 17h ago
Share
Listen to the news
- Reviva Pharmaceuticals stock set for Nasdaq suspension at open May 14, 2026, following Nasdaq Hearings Panel decision to delist for failing to regain compliance with Nasdaq Listing Rule 5550(a)(2) minimum $1 bid price by May 11, 2026.
- Quotation to move to OTCQB Venture Market on May 14, 2026 under existing symbol RVPH.
- Shift off Nasdaq expected to pressure liquidity, widen volatility, and constrain access to equity financing as shares fall under penny stock rules.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-016538), on May 13, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved